

# Carle F Paul

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7259952/carle-f-paul-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

347  
papers

14,660  
citations

68  
h-index

109  
g-index

396  
ext. papers

17,408  
ext. citations

4.3  
avg, IF

6.22  
L-index

#	Paper	IF	Citations
347	Skin manifestations of hypereosinophilic syndrome are polymorphous and difficult to treat: A retrospective cohort study.. <i>Annales De Dermatologie Et De Venereologie</i> , <b>2022</b> ,	0.3	
346	Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials.. <i>Acta Dermato-Venereologica</i> , <b>2022</b> ,	2.2	3
345	Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases.. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2022</b> , 1	12.3	0
344	Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review.. <i>American Journal of Clinical Dermatology</i> , <b>2022</b> , 1	7.1	1
343	Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 85, 360-368	4.5	10
342	Patient-reported outcomes from the JADE COMPARE randomised phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> ,	4.6	5
341	Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Psoriasis Patients from the PsoBioTeq Cohort. <i>Acta Dermato-Venereologica</i> , <b>2021</b> ,	2.2	1
340	Ca <sub>v</sub> 1.4 calcium channels control cytokine production by human peripheral T17 cells and psoriatic skin-infiltrating T cells. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> ,	11.5	1
339	Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey. <i>Dermatology and Therapy</i> , <b>2021</b> , 1	4	1
338	European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, e308-e311	4.6	12
337	Neuropsychiatric, cognitive and sexual impairment in mastocytosis patients. <i>Orphanet Journal of Rare Diseases</i> , <b>2021</b> , 16, 118	4.2	1
336	Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 1101-1112	59.2	54
335	How Oral Specialists Can Help Diagnose and Manage Extra-Digestive Inflammatory Bowel Disease Complications. <i>Case Reports in Gastroenterology</i> , <b>2021</b> , 15, 276-281	1	2
334	Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, e362-e365	4.6	14
333	Acrodermatitis enteropathica-like eruption secondary to vitamin and amino acid deficiencies associated with pancreatic tumour. <i>Annales De Dermatologie Et De Venereologie</i> , <b>2021</b> , 148, 133-135	0.3	
332	Cutaneous mastocytosis in adults with a serum tryptase level <i>British Journal of Dermatology</i> , <b>2021</b> , 185, 453-455	4	
331	Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, 1543-1552	4.6	10

330	What instruments should we add to our toolbox for measuring the severity and control of eczema?. <i>British Journal of Dermatology</i> , <b>2021</b> , 185, 13-14	4	
329	Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, 172-179	4.6	12
328	Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies. <i>British Journal of Dermatology</i> , <b>2021</b> , 184, 640-651	4	9
327	Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. <i>British Journal of Dermatology</i> , <b>2021</b> , 184, 50-59	4	50
326	Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, 450-457	4.6	7
325	Out-of-pocket expenditures in France to manage psoriasis in adult patients: results from an observational, cross-sectional, non-comparative, multicentre study. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, 912-918	4.6	0
324	De novo psoriasis in atopic dermatitis patients treated with dupilumab: a retrospective cohort. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, e296-e297	4.6	11
323	Unmet medical needs in the treatment of atopic dermatitis in infants: An Expert consensus on safety and efficacy of pimecrolimus. <i>Pediatric Allergy and Immunology</i> , <b>2021</b> , 32, 414-424	4.2	0
322	Analysis of non-responders to dupilumab in clinical practice: a cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, e192-e194	4.6	0
321	Langerhans cell histiocytosis associated with chronic myelomonocytic leukaemia both harbouring the same BRAF V600E mutation: efficacy of vemurafenib. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, e120-e121	4.6	2
320	How to assess patient satisfaction regarding physician interaction: A systematic review. <i>Dermatologic Therapy</i> , <b>2021</b> , 34, e14702	2.2	1
319	Efficacy and safety of fixed-dose combination calcipotriol/betamethasone dipropionate foam for the treatment of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35 Suppl 1, 10-19	4.6	2
318	Use of Complementary and Alternative Medicines by Patients with Psoriasis: Results from a Study with 2562 Patients. <i>American Journal of Clinical Dermatology</i> , <b>2021</b> , 22, 285-287	7.1	0
317	Bimekizumab versus Secukinumab in Plaque Psoriasis. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 142-152	5.2	38
316	Tapinarof-induced folliculitis: The paradigm of activation of the aryl hydrocarbon signaling pathway. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 85, e37-e38	4.5	3
315	Dermatose à IgA linéaire sur le compliqué d'une aspergillose invasive. <i>La Presse Médicale Formation</i> , <b>2021</b> , 2, 303-306	0	
314	Characteristics of patients with psoriasis with Psoriasis Area and Severity Index <i>British Journal of Dermatology</i> , <b>2021</b> , 185, 1052-1054	4	1
313	Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. <i>Journal of Dermatological Treatment</i> , <b>2021</b> , 1-8	2.8	2

312	Complications oculaires induites par le dupilumab au cours du traitement de la dermatite atopique. <i>Revue Francaise Diallergologie</i> , <b>2021</b> , 61, 592-592	0.2	
311	First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq. <i>Dermatology</i> , <b>2021</b> , 237, 338-346	4.4	0
310	Mastocytosis <b>2021</b> , 319-337		
309	A nationwide study evaluating the association of autoimmune bullous diseases and acquired haemophilia: description of clinical and prognostic features.. <i>British Journal of Dermatology</i> , <b>2021</b> ,	4	0
308	The biological basis of disease recurrence in psoriasis: a historical perspective and current models.. <i>British Journal of Dermatology</i> , <b>2021</b> ,	4	4
307	A Multicentre Randomised Controlled Study Evaluating the Effect of a Standardised Education Programme on Quality of Life, Disease Severity, and Disease Knowledge in Patients with Moderate-To-Severe Psoriasis: The EDUPSO Study. <i>Dermatology</i> , <b>2021</b> , 1-10	4.4	0
306	Profile of smoking dependency in hidradenitis suppurativa patients and smoking cessation outcomes. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, e790-e791	4.6	4
305	A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL). <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, 2566-2573	4.6	7
304	European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, e839-e842	4.6	8
303	Integrated multidisciplinary approach to hidradenitis suppurativa in clinical practice,. <i>International Journal of Womenis Dermatology</i> , <b>2020</b> , 6, 164-168	2	5
302	532 nm Q-switched laser for the treatment of hyperpigmentation induced by topical tacrolimus. <i>Journal of Cosmetic and Laser Therapy</i> , <b>2020</b> , 22, 90-92	1.8	1
301	European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection and atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, e241-e242	4.6	73
300	Omalizumab in the treatment of adult patients with mastocytosis: A systematic review. <i>Clinical and Experimental Allergy</i> , <b>2020</b> , 50, 654-661	4.1	21
299	Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 706-716	59.2	73
298	The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 83, 839-846	4.5	30
297	Impact of Atopic Dermatitis Lesion Location on Quality of Life in Adult Patients in a Real-world Study. <i>Journal of Drugs in Dermatology</i> , <b>2020</b> , 19, 943-948	2.2	2
296	Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect. <i>British Journal of Dermatology</i> , <b>2020</b> , 182, 1111-1119	4	27
295	Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, 301-309	4.6	16

294	Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. <i>Quality of Life Research</i> , <b>2020</b> , 29, 369-380	3.7	0
293	Quality of care in atopic dermatitis - a position statement by the European Task Force on Atopic Dermatitis (ETFAD). <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, e136-e138	4.6	5
292	Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. <i>Dermatology and Therapy</i> , <b>2020</b> , 10, 133-150	4	29
291	Latent class analysis categorizes chronic hand eczema patients according to skin barrier impairment. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, 1529-1535	4.6	4
290	Vascular Nd:YAG laser: a therapeutic alternative for large venous lakes of the oral mucosa. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, e164-e165	4.6	
289	ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, 2717-2744	4.6	56
288	Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL). <i>Dermatology and Therapy</i> , <b>2020</b> , 10, 1099-1109	4	4
287	The evolving field of Dermato-oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV-UEMS and EORTC Cutaneous Lymphoma Task Force. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, 2183-2197	4.6	10
286	Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. <i>British Journal of Dermatology</i> , <b>2020</b> , 182, 304-315	4	19
285	Positive change in hand care habits using therapeutic patient education in chronic hand eczema. <i>Contact Dermatitis</i> , <b>2020</b> , 82, 10-17	2.7	9
284	Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOSEQ. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, 293-300	4.6	20
283	European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2019</b> , 33, 1644-1659	4.6	42
282	Image Gallery: The vulva: an atypical localization of mastocytosis in adulthood. <i>British Journal of Dermatology</i> , <b>2019</b> , 181, e33	4	1
281	Long-term continuation with secukinumab in psoriasis: association with patient profile and initial psoriasis clearance. <i>Clinical and Experimental Dermatology</i> , <b>2019</b> , 44, e230-e234	1.8	8
280	Therapeutic patient education and self-management support for patients with psoriasis - a systematic review. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2019</b> , 17, 685-695	1.2	3
279	Efficacy of ixekizumab in patients with resistance or incomplete response to secukinumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2019</b> , 33, e338-e341	4.6	3
278	Frequency of isolated cutaneous involvement in adult mastocytosis: a cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2019</b> , 33, 1713-1718	4.6	4
277	An oral manifestation of IBD: Pyostomatitis vegetant, about two cases. <i>Journal of Stomatology, Oral and Maxillofacial Surgery</i> , <b>2019</b> , 120, 375-377	1.7	1

276	Higher prevalence of vertebral fractures in systemic mastocytosis, but not in cutaneous mastocytosis and idiopathic mast cell activation syndrome. <i>Osteoporosis International</i> , <b>2019</b> , 30, 1235-1241	5.3	3
275	Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey-based position statement. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2019</b> , 33, 807-815	4.6	5
274	Mast cell activation syndrome: High frequency of skin manifestations and anaphylactic shock. <i>Allergology International</i> , <b>2019</b> , 68, 119-121	4.4	
273	Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3. <i>Journal of Dermatological Treatment</i> , <b>2019</b> , 30, 19-26	2.8	15
272	Advanced Cutaneous Squamous Cell Carcinoma Is Associated with Suboptimal Initial Management in a Cohort of 109 Patients. <i>Dermatology</i> , <b>2019</b> , 235, 516-521	4.4	5
271	Therapeutische Patientenschulungsprogramme und Unterstützung beim Selbstmanagement für Patienten mit Psoriasis - eine systematische Übersicht. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2019</b> , 17, 685-697	1.2	
270	Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. <i>Lancet, The</i> , <b>2019</b> , 394, 576-586	4.0	121
269	Early necrotic skin lesions after a ABO-incompatible kidney transplantation: The threat of <i>Cunninghamella</i> Spp. <i>Transplant Infectious Disease</i> , <b>2019</b> , 21, e13173	2.7	0
268	Effect of dupilumab on atopic manifestations in patients treated for atopic dermatitis in real-life practice. <i>British Journal of Dermatology</i> , <b>2019</b> , 180, 1551-1552	4	22
267	Dermatology today and tomorrow: from symptom control to targeted therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2019</b> , 33 Suppl 1, 3-36	4.6	17
266	Compounded topical preparations in plaque psoriasis: Still a place for it in 2018?. <i>Dermatologic Therapy</i> , <b>2019</b> , 32, e12780	2.2	1
265	Prioritizing topics in guideline development: results of a two-phase online survey of dermatologist members of the EADV. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2019</b> , 33, 227-233	4.6	3
264	Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. <i>Journal of Investigative Dermatology</i> , <b>2019</b> , 139, 31-37	4.3	33
263	Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 70-79	4.5	58
262	Reversibility of alexithymia with effective treatment of moderate-to-severe psoriasis: longitudinal data from EPIDEPSO. <i>British Journal of Dermatology</i> , <b>2019</b> , 180, 397-403	4	8
261	Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 79, 266-276.e5	4.5	86
260	Infectious risk of biological drugs vs. traditional systemic treatments in moderate-to-severe psoriasis: a cohort analysis in the French insurance database. <i>Fundamental and Clinical Pharmacology</i> , <b>2018</b> , 32, 436-449	3.1	10
259	Focal facial hyperhidrosis associated with internal carotid artery dissection successfully treated with botulinum toxin A. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2018</b> , 32, e314-e316	4.6	1



258	Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum. <i>British Journal of Dermatology</i> , <b>2018</b> , 178, 1199-1203	4	17
257	Efficacy of ustekinumab in palmoplantar pustulosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2018</b> , 32, e204-e206	4.6	4
256	Stabilization of microtubules restores barrier function after cytokine-induced defects in reconstructed human epidermis. <i>Journal of Dermatological Science</i> , <b>2018</b> , 91, 87-96	4.3	6
255	Changes in interleukin-17A, macrophage-derived chemokine and adiponectin following treatment of psoriasis with calcipotriol plus betamethasone dipropionate aerosol foam: results from the PSO-ABLE study. <i>British Journal of Dermatology</i> , <b>2018</b> , 178, e33-e34	4	7
254	Trichodysplasia spinulosa associated with HIV infection: clinical response to acitretin and valganciclovir. <i>Clinical and Experimental Dermatology</i> , <b>2018</b> , 43, 231-233	1.8	8
253	Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). <i>British Journal of Dermatology</i> , <b>2018</b> , 178, 674-681	4	57
252	Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2018</b> , 32, 68-72	4.6	11
251	Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseases. <i>Clinical Immunology</i> , <b>2018</b> , 194, 75-79	9	6
250	Trends in hospitalization rates for psoriasis flares since the introduction of biologics: a time series in France between 2005 and 2015. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2018</b> , 32, 1920-1929	4.6	6
249	Characterization and Outcomes of Disease Progression in 52 Patients Treated with BRAF-V600 + MEK Inhibitors for Advanced Melanoma. <i>Dermatology</i> , <b>2018</b> , 234, 92-98	4.4	5
248	Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study. <i>European Journal of Dermatology</i> , <b>2018</b> , 28, 356-363	0.8	10
247	Extracorporeal Photopheresis: An Efficacious and Well-Tolerated Treatment for Cutaneous and Oral Mucosal Chronic Graft-versus-Host Disease. <i>Dermatology</i> , <b>2018</b> , 234, 23-30	4.4	4
246	Ixekizumab or secukinumab in psoriasis: what difference does it make?. <i>British Journal of Dermatology</i> , <b>2018</b> , 178, 1003-1005	4	15
245	Safety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical Trials. <i>Journal of Drugs in Dermatology</i> , <b>2018</b> , 17, 200-206	2.2	12
244	Tumour lysis syndrome: an unexpected adverse event associated with ipilimumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, e73-e74	4.6	13
243	Conflicts of interest and authorship of industry-sponsored publications. <i>British Journal of Dermatology</i> , <b>2017</b> , 176, 200-203	4	2
242	Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. <i>Lancet, The</i> , <b>2017</b> , 389, 612-620	4.0	72
241	Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, 847-856	4.6	31

240	A European subset analysis from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis shows country-specific features: results from psoriasis patients in Spain. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, 1176-1182	4.6	5
239	Systemic allergic contact dermatitis caused by methyl aminolaevulinate in a patient with keratosis-ichthyosis-deafness syndrome. <i>Contact Dermatitis</i> , <b>2017</b> , 76, 190-192	2.7	10
238	Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study. <i>American Journal of Clinical Dermatology</i> , <b>2017</b> , 18, 405-411	7.1	16
237	Non-surgical treatments for hidradenitis suppurativa: A systematic review. <i>Annales De Chirurgie Plastique Et Esthetique</i> , <b>2017</b> , 62, 274-294	1.1	18
236	Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, 1491-1496	4.6	36
235	Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. <i>British Journal of Dermatology</i> , <b>2017</b> , 177, 1014-1023	4	116
234	Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohort. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, 2046-2054	4.6	20
233	Systemic treatment of severe adult Atopic dermatitis in clinical practice: analysis of prescribing pattern in a cohort of 241 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, e423-e424	4.6	6
232	First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. <i>Lancet, The</i> , <b>2017</b> , 389, 2031-2040	40	287
231	Azathioprine Hypersensitivity Syndrome: Two Cases of Febrile Neutrophilic Dermatoses Induced by Azathioprine. <i>Case Reports in Dermatology</i> , <b>2017</b> , 9, 6-11	1.1	9
230	Authorship selection in industry-sponsored publications of dermatology clinical trials. <i>British Journal of Dermatology</i> , <b>2017</b> , 176, 1669-1671	4	5
229	Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study. <i>British Journal of Dermatology</i> , <b>2017</b> , 176, 1195-1203	4	26
228	Fixed combination calcipotriol plus betamethasone dipropionate aerosol foam in the treatment of psoriasis vulgaris: rationale for development and clinical profile. <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 115-121	4	12
227	Efficacy of hospital inpatient topical treatment for severe adult atopic dermatitis: a retrospective study of 56 patients. <i>European Journal of Dermatology</i> , <b>2017</b> , 27, 418-419	0.8	2
226	European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, 1951-1963	4.6	86
225	Prevalence and risk factors for fragility fracture in systemic mastocytosis. <i>Bone</i> , <b>2017</b> , 105, 219-225	4.7	20
224	Germline Loss-of-Function Mutations in EPHB4 Cause a Second Form of Capillary Malformation-Arteriovenous Malformation (CM-AVM2) Deregulating RAS-MAPK Signaling. <i>Circulation</i> , <b>2017</b> , 136, 1037-1048	16.7	130
223	Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, 119-126	4.6	68



222	Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, 294-303	4.6	7
221	Immunohistochemical staining for diagnosis of cutaneous mastocytosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, e160-e162	4.6	4
220	Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 76, 432-440.e175	4.75	88
219	Palmar erythema: inaugural manifestation of HIV infection. <i>European Journal of Dermatology</i> , <b>2017</b> , 27, 668-669	0.8	
218	Strategies used for measuring long-term control in atopic dermatitis trials: A systematic review. <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 75, 1038-1044	4.5	27
217	Photo-induced graft-versus-host disease. <i>Photodermatology Photoimmunology and Photomedicine</i> , <b>2016</b> , 32, 291-295	2.4	2
216	Improvement of Microstomia in Scleroderma after Carbon Dioxide Laser Treatment. <i>Case Reports in Dermatology</i> , <b>2016</b> , 8, 142-50	1.1	12
215	Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?. <i>Seminars in Arthritis and Rheumatism</i> , <b>2016</b> , 46, 291-304	5.3	84
214	Inclusion and exclusion criteria in phase III trials with systemic agents in psoriasis: the external validity of drug development. <i>British Journal of Dermatology</i> , <b>2016</b> , 175, 636-8	4	25
213	Acquired perforating dermatosis associated with sorafenib therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2016</b> , 30, 328-30	4.6	5
212	Staphylococcus aureus density on lesional and nonlesional skin is strongly associated with disease severity in atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 137, 1272-1274.e3	11.5	95
211	Telangiectasia macularis eruptiva perstans (TMEP): A form of cutaneous mastocytosis with potential systemic involvement. <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 74, 885-91.e1	4.5	17
210	Enzalutamide induced acute generalized exanthematous pustulosis. <i>Journal of Dermatological Case Reports</i> , <b>2016</b> , 10, 35-38		9
209	Botulinum Toxin A: An Effective Treatment for Linear Immunoglobulin A Bullous Dermatitis Located in the Axillae. <i>Acta Dermato-Venereologica</i> , <b>2016</b> , 96, 122-3	2.2	7
208	Active tuberculosis in psoriasis patients treated with TNF antagonists: a French nationwide retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2016</b> , 30, 1336-41	4.6	11
207	Antitumour necrosis factor- $\beta$ therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013. <i>British Journal of Dermatology</i> , <b>2016</b> , 174, 667-70	4	14
206	Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus. <i>British Journal of Dermatology</i> , <b>2016</b> , 175, 142-9	4	52
205	Surgical Treatment of Facial Basal Cell Carcinoma: Patient-Based Assessment of Clinical Outcome in a Prospective Cohort Study. <i>Dermatology</i> , <b>2016</b> , 232, 550-557	4.4	

204	Caractéristiques clinico-biologiques des mastocytoses suivies en rhumatologie. <i>Revue Du Rhumatisme (Edition Francaise)</i> , <b>2016</b> , 83, A136-A137	0.1	
203	Clinical meaningfulness of complete skin clearance in psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 75, 77-82.e7	4.5	65
202	Bone marrow tryptase as a possible diagnostic criterion for adult systemic mastocytosis. <i>Clinical and Experimental Allergy</i> , <b>2016</b> , 46, 133-41	4.1	7
201	Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2016</b> , 30, 1753-1759	4.6	34
200	A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , <b>2016</b> , 175, 273-86	4	297
199	Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 73, 242-8	4.5	146
198	Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper. <i>Journal of Dermatological Treatment</i> , <b>2015</b> , 26, 103-12	2.8	28
197	Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. <i>Lancet, The</i> , <b>2015</b> , 386, 541-51	4.0	576
196	Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 72, 992-1002	4.5	118
195	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1318-28	59.2	530
194	Angiolymphoid hyperplasia with eosinophilia treated with low-dose methotrexate. <i>JAAD Case Reports</i> , <b>2015</b> , 1, 342-4	1.4	3
193	GRAPPA Fellows Symposium Adjacent to the Swiss Psoriasis Day, Geneva, 2014: A Meeting Report. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1014-1015	4.1	1
192	Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2015</b> , 29, 1082-90	4.6	212
191	Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2015</b> , 29, 224-231	4.6	25
190	Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2015</b> , 29, 2002-10	4.6	104
189	Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). <i>British Journal of Dermatology</i> , <b>2015</b> , 173, 1387-99	4	288
188	Validation of treatment escalation as a definition of atopic eczema flares. <i>PLoS ONE</i> , <b>2015</b> , 10, e0124770	3.7	18
187	Interventions to Improve Adherence in Patients with Immune-Mediated Inflammatory Disorders: A Systematic Review. <i>PLoS ONE</i> , <b>2015</b> , 10, e0145076	3.7	31

186	Defects of corneocyte structural proteins and epidermal barrier in atopic dermatitis. <i>Biological Chemistry</i> , <b>2015</b> , 396, 1163-79	4.5	18
185	European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2015</b> , 29, 2277-94	4.6	271
184	Development and psychometric validation of the REFlective evaLUation of psoriasis Efficacy of Treatment and Severity (REFLETS) questionnaire: a common measure of plaque-type psoriasis severity and treatment efficacy for patients and clinicians. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2015</b> , 29, 498-506	4.6	10
183	Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants. <i>Pediatric Allergy and Immunology</i> , <b>2015</b> , 26, 306-15	4.2	64
182	Psoriasis de l'enfant: prise en charge pratique. <i>Journal De Pediatrie Et De Puericulture</i> , <b>2014</b> , 27, 1-8	0	
181	Observational case series on a group of psoriasis patients who failed to respond to any TNF blockers. <i>Journal of Dermatological Treatment</i> , <b>2014</b> , 25, 75-7	2.8	7
180	High-frequency ultrasonography but not 930-nm optical coherence tomography reliably evaluates melanoma thickness in vivo: a prospective validation study. <i>British Journal of Dermatology</i> , <b>2014</b> , 171, 799-805	4	23
179	One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , <b>2014</b> , 170, 435-44	4	32
178	Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT). <i>British Journal of Dermatology</i> , <b>2014</b> , 170, 425-34 <sup>4</sup>		18
177	Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2014</b> , 28, 1670-5	4.6	60
176	Point prevalence and risk factors for food allergy in a cohort of 386 children with atopic dermatitis attending a multidisciplinary dermatology/paediatric allergy clinic. <i>European Journal of Dermatology</i> , <b>2014</b> , 24, 63-9	0.8	8
175	Knockdown of filaggrin in a three-dimensional reconstructed human epidermis impairs keratinocyte differentiation. <i>Journal of Investigative Dermatology</i> , <b>2014</b> , 134, 2938-2946	4.3	80
174	Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 70, 871-81.e1-30	4.5	332
173	Factors associated with sun protection compliance: results from a nationwide cross-sectional evaluation of 2215 patients from a dermatological consultation. <i>British Journal of Dermatology</i> , <b>2014</b> , 170, 1327-35	4	10
172	Breslow thickness, clark index and ulceration are associated with sentinel lymph node metastasis in melanoma patients: a cohort analysis of 612 patients. <i>Dermatology</i> , <b>2014</b> , 229, 183-9	4.4	12
171	Treatment (biotherapy excluded) of psoriatic arthritis: an appraisal of methodological quality of international guidelines. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2014</b> , 28 Suppl 5, 33-9	4.6	6
170	Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2014</b> , 28 Suppl 5, 17-26	4.6	56
169	Evidence-based recommendations on the role of dermatologists in the diagnosis and management of psoriatic arthritis: systematic review and expert opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2014</b> , 28 Suppl 5, 3-12	4.6	16

168	Bleomycin hydrolase downregulation in lesional skin of adult atopic dermatitis patients is independent of FLG gene mutations. <i>Journal of Allergy and Clinical Immunology</i> , <b>2014</b> , 134, 1459-1461.e7	11.5	12
167	Consensus recommendations for the treatment of basal cell carcinomas in Gorlin syndrome with topical methylaminolaevulinate-photodynamic therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2014</b> , 28, 626-32	4.6	25
166	Healthcare cost impact of biological drugs compared with traditional systemic treatments in psoriasis: a cohort analysis in the French insurance database. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2014</b> , 28, 1235-44	4.6	16
165	Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2013</b> , 27 Suppl 3, 12-29	4.6	199
164	Alcohol consumption and psoriasis: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2013</b> , 27 Suppl 3, 30-5	4.6	74
163	CD10 expression by melanoma cells is associated with aggressive behavior in vitro and predicts rapid metastatic progression in humans. <i>Journal of Dermatological Science</i> , <b>2013</b> , 69, 105-13	4.3	10
162	Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin. <i>Journal of Allergy and Clinical Immunology</i> , <b>2013</b> , 131, 1094-102	11.5	168
161	Buprenorphine-induced linear IgA bullous dermatosis "down the rail". <i>Journal of the American Academy of Dermatology</i> , <b>2013</b> , 69, e106-7	4.5	2
160	Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. <i>British Journal of Dermatology</i> , <b>2013</b> , 168, 402-11	4	90
159	Is conjunctival mucous involvement a marker of severity in pemphigus vulgaris?. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2013</b> , 27, 520-1	4.6	4
158	Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2013</b> , 27 Suppl 3, 36-46	4.6	131
157	Efficacy, safety and tolerability of an optimized avulsion technique with onyster <sup>®</sup> (40% urea ointment with plastic dressing) ointment compared to bifonazole-urea ointment for removal of the clinically infected nail in toenail onychomycosis: a randomized evaluator-blinded controlled study. <i>Dermatology</i> , <b>2013</b> , 227, 5-10	4.4	18
156	A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. <i>British Journal of Dermatology</i> , <b>2013</b> , 168, 1080-7	4	64
155	A multicenter, randomized, open-label, controlled study comparing the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution with amorolfine nail lacquer alone in dermatophytic onychomycosis. <i>Dermatology</i> , <b>2013</b> , 227, 157-64	4.4	13
154	Late-onset X-linked dominant protoporphyria: an etiology of photosensitivity in the elderly. <i>Journal of Investigative Dermatology</i> , <b>2013</b> , 133, 1688-90	4.3	10
153	Nickel-induced systemic contact dermatitis and intratubal implants: the baboon syndrome revisited. <i>Dermatitis</i> , <b>2013</b> , 24, 35-6	2.6	22
152	Psoriasis, cardiovascular events, cancer risk and alcohol use: evidence-based recommendations based on systematic review and expert opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2013</b> , 27 Suppl 3, 2-11	4.6	36
151	Incidence and risk factors for treatment failure with infliximab in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2013</b> , 27, 1323-4	4.6	5

150	Socioeconomic outcomes following spinal cord injury and the role of no-fault compensation: longitudinal study. <i>Spinal Cord</i> , <b>2013</b> , 51, 919-25	2.7	19
149	Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France. <i>British Journal of Dermatology</i> , <b>2012</b> , 167, 643-8	4	24
148	Evidence-based recommendations on topical treatment and phototherapy of psoriasis: systematic review and expert opinion of a panel of dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2012</b> , 26 Suppl 3, 1-10	4.6	43
147	Efficacy of psoralen UV-A therapy vs. narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2012</b> , 26 Suppl 3, 11-21	4.6	53
146	Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2012</b> , 26 Suppl 3, 22-31	4.6	174
145	Ocular damage in patients with psoriasis treated by psoralen UV-A therapy or narrow band UVB therapy: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2012</b> , 26 Suppl 3, 32-5	4.6	10
144	Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2012</b> , 26 Suppl 3, 36-46	4.6	19
143	Topical corticosteroids in plaque psoriasis: a systematic review of risk of adrenal axis suppression and skin atrophy. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2012</b> , 26 Suppl 3, 47-51	4.6	41
142	Topical vitamin D analogues alone or in association with topical steroids for psoriasis: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2012</b> , 26 Suppl 3, 52-60	4.6	35
141	Adherence to topical treatment in psoriasis: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2012</b> , 26 Suppl 3, 61-7	4.6	127
140	Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2012</b> , 67, 1111-7	9.3	137
139	Simultaneous cutaneous infection due to <i>Paecilomyces lilacinus</i> and <i>Alternaria</i> in a heart transplant patient. <i>Transplant Infectious Disease</i> , <b>2012</b> , 14, E156-60	2.7	12
138	Quantification of <i>Demodex folliculorum</i> by PCR in rosacea and its relationship to skin innate immune activation. <i>Experimental Dermatology</i> , <b>2012</b> , 21, 906-10	4	109
137	New topical drug development in atopic dermatitis: a place for hope. <i>British Journal of Dermatology</i> , <b>2012</b> , 166, 711	4	
136	Psoriasis: rationale for targeting interleukin-17. <i>British Journal of Dermatology</i> , <b>2012</b> , 167, 717-24	4	103
135	Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. <i>British Journal of Dermatology</i> , <b>2012</b> , 167, 1138-44	4	75
134	Contact photoallergy to isothipendyl chlorhydrate. <i>Dermatology</i> , <b>2012</b> , 224, 289-91	4.4	11
133	Update on the epidermal differentiation complex. <i>Frontiers in Bioscience - Landmark</i> , <b>2012</b> , 17, 1517-32	2.8	95



132	Patient satisfaction with injection devices: a randomized controlled study comparing two different etanercept delivery systems in moderate to severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2012</b> , 26, 448-55	4.6	16
131	In vivo quantification of epidermis pigmentation and dermis papilla density with reflectance confocal microscopy: variations with age and skin phototype. <i>Experimental Dermatology</i> , <b>2012</b> , 21, 281-6 <sup>4</sup>		4 <sup>0</sup>
130	Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis. <i>Archives of Dermatology</i> , <b>2012</b> , 148, 1423-5		37
129	Prognostic factors of paraneoplastic pemphigus. <i>Archives of Dermatology</i> , <b>2012</b> , 148, 1165-72		99
128	Why statistics matter: limited inter-rater agreement prevents using the psoriasis area and severity index as a unique determinant of therapeutic decision in psoriasis. <i>Journal of Investigative Dermatology</i> , <b>2012</b> , 132, 2171-5	4.3	35
127	Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study. <i>European Journal of Dermatology</i> , <b>2012</b> , 22, 762-9	0.8	19
126	Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. <i>British Journal of Dermatology</i> , <b>2012</b> , 168, no-no	4	184
125	Photoletter to the editor: Blue nevus with satellitosis mimicking melanoma. Contribution of dermoscopy and reflectance confocal microscopy. <i>Journal of Dermatological Case Reports</i> , <b>2012</b> , 6, 54-6		4
124	Management of autoimmune bullous diseases in France: a nationwide network of 30 centers. <i>Dermatologic Clinics</i> , <b>2011</b> , 29, 659-62	4.2	0
123	Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis. <i>American Journal of Medicine</i> , <b>2011</b> , 124, 776-8	2.4	34
122	High-resolution magnetic resonance imaging in study of the skin: normal patterns. <i>European Journal of Radiology</i> , <b>2011</b> , 80, e176-81	4.7	17
121	Efficacy and tolerability of methotrexate in severe childhood alopecia areata. <i>British Journal of Dermatology</i> , <b>2011</b> , 165, 407-10	4	48
120	Are we giving patients enough information on how to use topical treatments? Analysis of 767 prescriptions in psoriasis. <i>British Journal of Dermatology</i> , <b>2011</b> , 165, 1332-6	4	16
119	Topical methyl aminolevulinate photodynamic therapy for management of basal cell carcinomas in patients with basal cell nevus syndrome improves patient's satisfaction and reduces the need for surgical procedures. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2011</b> , 25, 861-4	4.6	17
118	Joint clinical and pathological review meetings improve patient care: a prospective evaluation in dermatology. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2011</b> , 25, 928-32	4.6	1
117	Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2011</b> , 25, 1238-40	4.6	47
116	Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2011</b> , 25 Suppl 2, 2-11	4.6	52
115	Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2011</b> , 25 Suppl 2, 12-8	4.6	108

114	Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2011</b> , 25 Suppl 2, 19-27	4.6	69
113	Efficacy and safety of oral retinoids in different psoriasis subtypes: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2011</b> , 25 Suppl 2, 28-33	4.6	37
112	Traitement du psoriasis en pratique pour le rhumatologue. <i>Revue Du Rhumatisme Monographies</i> , <b>2011</b> , 78, 145-151	0	0
111	Cytophagic histiocytic panniculitis after H1N1 vaccination: a case report and review of the cutaneous side effects of influenza vaccines. <i>Dermatology</i> , <b>2011</b> , 222, 217-20	4.4	3
110	Hornerin is a component of the epidermal cornified cell envelopes. <i>FASEB Journal</i> , <b>2011</b> , 25, 1567-76	0.9	67
109	Prevalence and risk factors for xerosis in the elderly: a cross-sectional epidemiological study in primary care. <i>Dermatology</i> , <b>2011</b> , 223, 260-5	4.4	89
108	Deimination of human filaggrin-2 promotes its proteolysis by calpain 1. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 23222-33	5.4	55
107	Psoriasis evaluation in clinical practice: systematic review and expert opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2010</b> , 24 Suppl 2, 1	4.6	1
106	Evidence-based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2010</b> , 24 Suppl 2, 2-9	4.6	44
105	What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2010</b> , 24 Suppl 2, 10-6	4.6	170
104	What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2010</b> , 24 Suppl 2, 17-22	4.6	86
103	Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2010</b> , 24 Suppl 2, 23-30	4.6	98
102	Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2010</b> , 24 Suppl 2, 31-5	4.6	101
101	Psoriasis: an epidemiological evaluation of disease burden in 590 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2010</b> , 24, 1075-82	4.6	69
100	Prevalence and prognostic value of cutaneous manifestations in patients with myelodysplastic syndrome. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2010</b> , 24, 1171-5	4.6	25
99	Purpuric lesions induced by UVA1 spectrum (340-400 nm) phototesting in an adult with persistent and severe hydroa vacciniforme. <i>Photodermatology Photoimmunology and Photomedicine</i> , <b>2010</b> , 26, 104-6 <sup>4</sup>		
98	Histological regression in primary melanoma: not a predictor of sentinel lymph node metastasis in a cohort of 397 patients. <i>British Journal of Dermatology</i> , <b>2010</b> , 162, 830-4	4	29
97	Iatrogenic adrenal insufficiency associated with calcipotriol-betamethasone topical combination in psoriasis. <i>Clinical and Experimental Dermatology</i> , <b>2010</b> , 35, e167-8	1.8	7

96	Childhood chilblains is an uncommon and invalidant disease. <i>Archives of Disease in Childhood</i> , <b>2010</b> , 95, 567-8	2.2	10
95	Pruritus in cutaneous T-cell lymphomas: frequent, often severe and difficult to treat. <i>Acta Dermato-Venereologica</i> , <b>2010</b> , 90, 12-7	2.2	36
94	Efficacy of ustekinumab in palmoplantar psoriasis. <i>Dermatology</i> , <b>2010</b> , 221, 321-3	4.4	25
93	Incidence of auto-immune pemphigus in the Midi-Pyrénées region in 2002-2006. <i>Dermatology</i> , <b>2010</b> , 220, 97-102	4.4	7
92	Dermatite atopique de l'enfant : quand penser à l'allergie alimentaire ?. <i>Revue Française d'Allergologie</i> , <b>2010</b> , 50, S14-S20	0.2	0
91	Segmental and nonsegmental childhood vitiligo has distinct clinical characteristics: a prospective observational study. <i>Journal of the American Academy of Dermatology</i> , <b>2010</b> , 62, 945-9	4.5	55
90	Albright hereditary osteodystrophy: report of a particular clinical phenotype caused by a novel GNAS mutation. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2010</b> , 24, 974-5	4.6	3
89	Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. <i>American Journal of Hematology</i> , <b>2010</b> , 85, 921-5	7.1	80
88	Cutaneous T cell lymphoma complicating severe atopic dermatitis. Is making a diagnosis the main challenge?. <i>Dermatology</i> , <b>2009</b> , 218, 168-71	4.4	13
87	Pharmacological treatment (biotherapy excluded) of peripheral psoriatic arthritis: development of recommendations for clinical practice based on data from the literature and experts opinion. <i>Joint Bone Spine</i> , <b>2009</b> , 76, 524-31	2.9	13
86	Prognosis and follow-up of psoriatic arthritis with peripheral joint involvement: development of recommendations for clinical practice based on published evidence and expert opinion. <i>Joint Bone Spine</i> , <b>2009</b> , 76, 540-6	2.9	8
85	Diagnosis of peripheral psoriatic arthritis: recommendations for clinical practice based on data from the literature and experts opinion. <i>Joint Bone Spine</i> , <b>2009</b> , 76, 532-9	2.9	19
84	Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. <i>British Journal of Dermatology</i> , <b>2009</b> , 160, 622-8	4	91
83	Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases. <i>British Journal of Dermatology</i> , <b>2009</b> , 161, 660-3	4	42
82	CONSORT adoption and quality of reporting of randomized controlled trials: a systematic analysis in two dermatology journals. <i>British Journal of Dermatology</i> , <b>2009</b> , 161, 1159-65	4	50
81	Cancer risk evaluation in psoriasis: in search of the Holy Grail?. <i>Journal of Investigative Dermatology</i> , <b>2009</b> , 129, 2547-9	4.3	3
80	Milia complicating bullous polymorphic light eruption. <i>Photodermatology Photoimmunology and Photomedicine</i> , <b>2009</b> , 25, 51-2	2.4	0
79	Prevalence and risk factors for allergic contact dermatitis to topical treatment in atopic dermatitis: a study in 641 children. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2009</b> , 64, 801-6	9.3	109

78	Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2009</b> , 23, 967-8	4.6	16
77	Moderate to severe psoriasis: from topical to biological treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2009</b> , 23, 1324-6	4.6	13
76	Immunosupresores sistèmicos en dermatologÌa. <i>EMC - DermatologÌa</i> , <b>2008</b> , 42, 1-15	0.1	
75	Photodistribution of blue-gray hyperpigmentation after amiodarone treatment: molecular characterization of amiodarone in the skin. <i>Archives of Dermatology</i> , <b>2008</b> , 144, 92-6		31
74	Immunosupresseurs systèmiques en dermatologie. <i>EMC - Dermatologie</i> , <b>2008</b> , 3, 1-14		
73	Carbimazole-induced juvenile dermatomyositis. <i>British Journal of Dermatology</i> , <b>2008</b> , 158, 196-7	4	5
72	Distal Madelung-Launois-Bensaude disease: an unusual differential diagnosis of acromelic arthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2008</b> , 26, 351-3	2.2	4
71	Diagnostic du rhumatisme psoriasique de forme pèriphèrique : laboration de recommandations pour la pratique clinique, à partir d'une analyse systèmique de la littèrature et de l'opinion d'experts: Diagnosis of peripheral psoriatic arthritis: recommendations for clinical practice based on a systematic analysis of the literature and experts' opinion. <i>Revue Du Rhumatisme (Edition Francaise)</i> , <b>2007</b> , 74, 15-22	0.1	1
70	Pronostic et suivi du rhumatisme psoriasique de forme pèriphèrique : laboration de recommandations pour la pratique clinique, à partir d'une analyse systèmique de la littèrature et de l'opinion d'experts. <i>Revue Du Rhumatisme (Edition Francaise)</i> , <b>2007</b> , 74, 23-30	0.1	
69	Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. <i>Journal of Investigative Dermatology</i> , <b>2007</b> , 127, 808-16	4.3	184
68	Les traitements mèdicamenteux (hors biothèrapie) dans la prise en charge de patients atteints de rhumatisme psoriasique pèriphèrique : laboration de recommandations pour la pratique clinique, à partir d'une analyse systèmique de la littèrature et de l'opinion d'experts: Pharmacological treatment (biotherapy excluded) of peripheral psoriatic arthritis: development of recommendations for clinical practice based on a systematic analysis of the literature and experts' opinion. <i>Revue Du Rhumatisme (Edition Francaise)</i> , <b>2007</b> , 74, 31-38	0.1	
67	A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. <i>British Journal of Dermatology</i> , <b>2007</b> , 157, 954-9	4	52
66	Blood concentrations, tolerability and efficacy of pimecrolimus cream 1% in Japanese infants and children with atopic dermatitis. <i>Journal of Dermatology</i> , <b>2007</b> , 34, 231-6	1.6	15
65	Cellular phone addiction and allergic contact dermatitis to nickel. <i>Contact Dermatitis</i> , <b>2007</b> , 57, 130-1	2.7	25
64	Contact dermatitis to hydrolyzed wheat protein. <i>Contact Dermatitis</i> , <b>2007</b> , 57, 283-4	2.7	15
63	Potential new indications of topical calcineurin inhibitors. <i>Dermatology</i> , <b>2007</b> , 215 Suppl 1, 45-54	4.4	51
62	An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance. <i>Dermatology</i> , <b>2007</b> , 215 Suppl 1, 27-44	4.4	36
61	Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients. <i>Dermatology</i> , <b>2007</b> , 215 Suppl 1, 3-17	4.4	24

60	Conflicts of interest in dermatology. <i>Acta Dermato-Venereologica</i> , <b>2006</b> , 86, 485-97	2.2	16
59	Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. <i>Pediatrics</i> , <b>2006</b> , 117, e118-28	7.4	90
58	Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2006</b> , 61, 375-81	9.3	44
57	Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2006</b> , 20, 248-54	4.6	28
56	Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. <i>Journal of the American Academy of Dermatology</i> , <b>2005</b> , 52, 247-53	4.5	64
55	Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. <i>Journal of the American Academy of Dermatology</i> , <b>2005</b> , 52, 240-6	4.5	85
54	Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. <i>Journal of the American Academy of Dermatology</i> , <b>2005</b> , 53, 602-9	4.5	52
53	Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. <i>British Journal of Dermatology</i> , <b>2005</b> , 152, 1219-27	4.4	44
52	Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. <i>British Journal of Dermatology</i> , <b>2005</b> , 152, 1298-303	4.4	38
51	Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study. <i>Dermatology</i> , <b>2004</b> , 209, 301-7	4.4	135
50	Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. <i>British Journal of Dermatology</i> , <b>2004</b> , 150, 96-102	4	113
49	Ciclosporin in psoriasis clinical practice: an international consensus statement. <i>British Journal of Dermatology</i> , <b>2004</b> , 150 Suppl 67, 11-23	4	115
48	Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis. <i>International Journal of Dermatology</i> , <b>2004</b> , 43, 978-83	1.7	29
47	Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. <i>Journal of Dermatological Treatment</i> , <b>2004</b> , 15, 169-78	2.8	79
46	Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. <i>Journal of Investigative Dermatology</i> , <b>2003</b> , 120, 211-6	4.3	257
45	Treating severe psoriasis: how to navigate safely between scylla and charybdis?. <i>Journal of Investigative Dermatology</i> , <b>2003</b> , 121, ix-x	4.3	2
44	Importance of trial design in studies using high-dose intravenous immunoglobulin: reply from authors. <i>British Journal of Dermatology</i> , <b>2003</b> , 148, 1285-1286	4	1
43	Terbinafine (Lamisil) treatment of toenail onychomycosis in patients with insulin-dependent and non-insulin-dependent diabetes mellitus: a multicentre trial. <i>British Journal of Dermatology</i> , <b>2002</b> , 146, 254-60	4	29



42	A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to <i>Microsporum</i> species. <i>British Journal of Dermatology</i> , <b>2002</b> , 146, 816-23	4	73
41	A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. <i>British Journal of Dermatology</i> , <b>2002</b> , 147, 518-22	4	94
40	Prognostic factors of mycological cure following treatment of onychomycosis with oral antifungal agents. <i>British Journal of Dermatology</i> , <b>2002</b> , 147, 1241-3	4	22
39	Topical tacrolimus and pimecrolimus are not associated with skin atrophy: reply from author. <i>British Journal of Dermatology</i> , <b>2002</b> , 146, 343-343	4	
38	Terbinafine in the treatment of <i>Trichophyton</i> tinea capitis: a randomized, double-blind, parallel-group, duration-finding study. <i>Pediatrics</i> , <b>2002</b> , 109, 602-7	7.4	73
37	Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study. <i>Dermatology</i> , <b>2002</b> , 205, 383-8	4.4	38
36	One-week terbinafine 1% solution in pityriasis versicolor: twice-daily application is more effective than once-daily. <i>Journal of Dermatological Treatment</i> , <b>2002</b> , 13, 39-40	2.8	7
35	Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. <i>Archives of Dermatology</i> , <b>2002</b> , 138, 353-7		151
34	Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. <i>Pediatrics</i> , <b>2002</b> , 110, e2	7.4	244
33	Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. <i>Journal of Clinical Pharmacology</i> , <b>2002</b> , 42, 1211-8	2.9	38
32	Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. <i>Journal of Allergy and Clinical Immunology</i> , <b>2002</b> , 110, 277-84	11.5	206
31	The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. <i>British Journal of Dermatology</i> , <b>2001</b> , 144, 507-13	4	204
30	Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. <i>British Journal of Dermatology</i> , <b>2001</b> , 144, 967-72	4	106
29	Long-term efficacy of antifungals in toenail onychomycosis: a critical review. <i>British Journal of Dermatology</i> , <b>2001</b> , 145, 446-52	4	33
28	One week terbinafine 1% cream (Lamisil) once daily is effective in the treatment of interdigital tinea pedis: a vehicle controlled study. LAS-INT-06 Study Group. <i>Medical Mycology</i> , <b>2001</b> , 39, 335-40	3.9	29
27	Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. <i>Journal of the American Academy of Dermatology</i> , <b>2001</b> , 44, 643-51	4.5	117
26	Regulation of expression of the rat SOCS-3 gene in hepatocytes by growth hormone, interleukin-6 and glucocorticoids mRNA analysis and promoter characterization. <i>FEBS Journal</i> , <b>2000</b> , 267, 5849-57		58
25	Ascomycins: promising agents for the treatment of inflammatory skin diseases. <i>Expert Opinion on Investigational Drugs</i> , <b>2000</b> , 9, 69-77	5.9	56

24	Enhanced surveillance of HIV infections in New Zealand, 1996-1998. <i>New Zealand Medical Journal</i> , <b>2000</b> , 113, 390-4	0.8	9
23	Risk of malignancy associated with cyclosporin use in psoriasis. <i>Dermatology</i> , <b>1999</b> , 198, 320-1	4.4	11
22	Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. <i>British Journal of Dermatology</i> , <b>1999</b> , 141, 283-91	4	99
21	A prospective coagulation study including resistance to activated protein C and mutations in factors V and II in venous leg ulcers. <i>British Journal of Dermatology</i> , <b>1999</b> , 141, 259-63	4	15
20	EMLA cream as a topical anesthetic for the repeated mechanical debridement of venous leg ulcers: a double-blind, placebo-controlled study. <i>Journal of the American Academy of Dermatology</i> , <b>1999</b> , 40, 208-13	4.5	55
19	Epidermodysplasia verruciformis-like eruption complicating human immunodeficiency virus infection. <i>British Journal of Dermatology</i> , <b>1998</b> , 139, 122-7	4	54
18	Ascomycins in dermatology. <i>Seminars in Cutaneous Medicine and Surgery</i> , <b>1998</b> , 17, 256-9	1.4	17
17	Cutaneous effects of granulocyte colony-stimulating factor in healthy volunteers. <i>Archives of Dermatology</i> , <b>1998</b> , 134, 111-2		20
16	Dermatite atopique Traitements actuels et traitements d'avenir. <i>Revue Francaise Diallergologie Et Diimmunologie Clinique</i> , <b>1997</b> , 37, 361-366		
15	Screening for hepatitis B carriers: a perspective from New Zealand. <i>Australian and New Zealand Journal of Medicine</i> , <b>1997</b> , 27, 698-705		1
14	Drug-induced linear IgA disease: target antigens are heterogeneous. <i>British Journal of Dermatology</i> , <b>1997</b> , 136, 406-411	4	39
13	Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis. <i>Archives of Dermatology</i> , <b>1997</b> , 133, 867-871		42
12	More on cutaneous reactions to recombinant cytokine therapy. <i>Journal of the American Academy of Dermatology</i> , <b>1996</b> , 35, 650-1	4.5	14
11	Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. <i>British Journal of Dermatology</i> , <b>1996</b> , 134, 710-4	4	202
10	Heterosexual behaviour and HIV risk in New Zealand: data from a national survey. <i>Australian Journal of Public Health</i> , <b>1995</b> , 19, 13-8		18
9	Oral contraceptive use and risk of breast cancer in older women (New Zealand). <i>Cancer Causes and Control</i> , <b>1995</b> , 6, 485-91	2.8	2
8	Hyperkeratotic spicules and monoclonal gammopathy. <i>Journal of the American Academy of Dermatology</i> , <b>1995</b> , 33, 346-51	4.5	31
7	Infection due to <i>Klebsiella rhinoscleromatis</i> in two patients infected with human immunodeficiency virus. <i>Clinical Infectious Diseases</i> , <b>1993</b> , 16, 441-2	11.6	21

6	Alternative Splicing Is Responsible for the Presence of Two Tissue Factor mRNA Species in LPS Stimulated Human Monocytes. <i>Thrombosis and Haemostasis</i> , <b>1992</b> , 67, 272-276	7	21
5	Chromoblastomycosis with malignant transformation and cutaneous-synovial secondary localization. The potential therapeutic role of itraconazole. <i>Medical Mycology</i> , <b>1991</b> , 29, 313-6	3.9	10
4	Oral contraceptives and risk of breast cancer. <i>International Journal of Cancer</i> , <b>1990</b> , 46, 366-73	7.5	49
3	No new evidence on the cervical cancer study. <i>New Zealand Medical Journal</i> , <b>1990</b> , 103, 581-3	0.8	2
2	Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer. <i>BMJ: British Medical Journal</i> , <b>1989</b> , 299, 759-62		60
1	The New Zealand cervical cancer study: could it happen again?. <i>BMJ: British Medical Journal</i> , <b>1988</b> , 297, 533-9		18